Cyclo Therapeutics Inc (CYTH)

[JellyDonut]

We are currently developing.

Where in that sentence does it say they are actively using their drug or families are using their drug? Nowhere, because it is not.

Q: What else is being done to address this unmet medical need?
A: Vtesse was launched in 2015 with the sole purpose of rapidly developing and bringing to market drugs for NPC. We appreciate the urgent need to develop a treatment for NPC and are working in collaboration with clinicians, patient groups and regulatory agencies to launch a clinical development program. We are currently developing and plan to seek regulatory approval for VTS-270 (a proprietary formulation of cyclodextrin) to treat patients with NPC.

Vtesse will design and lead a pivotal VTS-270 clinical study for the treatment of NPC. Vtesse will conduct the clinical study at several sites across the United States and in Europe.